GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Fujian Cosunter Pharmaceutical Co Ltd (SZSE:300436) » Definitions » 5-Year EBITDA Growth Rate

Fujian Cosunter Pharmaceutical Co (SZSE:300436) 5-Year EBITDA Growth Rate : 0.00% (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Fujian Cosunter Pharmaceutical Co 5-Year EBITDA Growth Rate?

Fujian Cosunter Pharmaceutical Co's EBITDA per Share for the three months ended in Sep. 2024 was ¥-0.17.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Fujian Cosunter Pharmaceutical Co was 72.80% per year. The lowest was -45.00% per year. And the median was -7.70% per year.


Competitive Comparison of Fujian Cosunter Pharmaceutical Co's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Fujian Cosunter Pharmaceutical Co's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fujian Cosunter Pharmaceutical Co's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fujian Cosunter Pharmaceutical Co's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Fujian Cosunter Pharmaceutical Co's 5-Year EBITDA Growth Rate falls into.


;

Fujian Cosunter Pharmaceutical Co 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Fujian Cosunter Pharmaceutical Co  (SZSE:300436) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.


Fujian Cosunter Pharmaceutical Co 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Fujian Cosunter Pharmaceutical Co's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Fujian Cosunter Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
Software Park, No. 89, Software Avenue, Block B, Building 10, Zone B, Gulou District, Fujian, Fuzhou, CHN, 350003
Fujian Cosunter Pharmaceutical Co Ltd is a pharmaceutical company engaged in the pharmaceutical production, sales and Research and Development. Its specialized in the field of hepatitis B medicine. Its product includes Fuganding-tenofovir disoproxil fumarate capsule, Enganding-Entecavir Capsules, He Ganding-Lamifuzed tablets and Agandan-adefovir dipivoxil tablets.
Executives
Li Guo Ping Directors, executives
Huang Fu Hu Directors, executives
Li Hong Ming Directors, executives
Guan Jian Hui Executives
Lin Xiao Hui Directors, Directors, and Executives
Ye Li Qing Director
Li Yuan Li Supervisors
Zheng Li Feng Supervisors
Li Guo Dong Directors, executives

Fujian Cosunter Pharmaceutical Co Headlines

No Headlines